Nuvation Bio Q2 Earnings Call Highlights
· finance.yahoo.com
Nuvation Bio (NYSE:NUVB) reported second-quarter total revenue of $31.7 million, including $23.2 million in net U.S. product revenue from IBTROZI, as the company said use of the ROS1-targeted lung cancer therapy continued to shift toward first-line patients. IBTROZI revenue increased 25% from the f
Chief Commercial Officer Colleen Sjogren said IQVIA claims data from January through May showed IBTROZI was the most prescribed ROS1 tyrosine kinase inhibitor, ...